Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Wockhardt's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹1,890 Mil. Wockhardt's Revenue for the
three
months ended in Mar. 2026 was ₹9,650 Mil. Therefore, Wockhardt's pretax margin for the quarter that ended in Mar. 2026 was 19.59%.
The historical rank and industry rank for Wockhardt's Pretax Margin % or its related term are showing as below:
NSE:WOCKPHARMA'
s Pretax Margin % Range Over the Past 10 Years
Min: -23.58 Med: -12.7 Max: 7.06
Current: 7.06
NSE:WOCKPHARMA's Pretax Margin % is ranked worse than 50.73% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs NSE:WOCKPHARMA: 7.06
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Wockhardt Pretax Margin % Related Terms
Wockhardt Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Wockhardt's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WOCKPHARMA vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Wockhardt's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a Pretax Margin % of 19.59% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Wockhardt and its competitors. According to the industry distribution chart, Wockhardt ranks #487 out of 960 companies in the Drug Manufacturers industry, placing it in the top 50.7%.
Is Wockhardt's Pretax Margin % too high?
Wockhardt's current Pretax Margin % is 19.59%. The Drug Manufacturers industry median Pretax Margin % is 7.29. Wockhardt's value of 19.59% is 168.9% above this industry median. Based on the distribution chart, Wockhardt ranks #487 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wockhardt has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #487 out of 960 companies for Pretax Margin %. This places Wockhardt in the lower half of its industry. The industry median Pretax Margin % is 7.29. Wockhardt's value of 19.59% is 168.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current Pretax Margin % of 19.59% is 168.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Pretax Margin % is 19.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,268.66, compared to a current price of ₹1,900.70 — trading 49.8% above its estimated fair value. The current Pretax Margin % is 19.59% and 168.9% above the Drug Manufacturers industry median of 7.29. Wockhardt's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Pretax Margin % is 19.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,900.70 is trading 49.8% above its estimated GF Value™ of ₹1,268.66.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
Pretax Margin %: 19.59%
GF Value™: ₹1,268.66 vs. price of ₹1,900.70 (49.8% above fair value)
Industry Position: 168.9% above the Drug Manufacturers median (#487 of 960)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
59GF Score
Get the complete analysis for NSE:WOCKPHARMA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
